- Molecular NameTorasemide
- SynonymTorasemida [INN-Spanish]; Torasemidum [INN-Latin]; Torsemide
- Weight348.427
- Drugbank_IDDB00214
- ACS_NO56211-40-6
- Show 3D model
- LogP (experiment)3.37
- LogP (predicted, AB/LogP v2.0)3.21
- pka6.44, 7.1
- LogD (pH=7, predicted)2.7
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-2.11
- LogSw (predicted, AB/LogsW2.0)0.14
- Sw (mg/ml) (predicted, ACD/Labs)0.03
- No.of HBond Donors3
- No.of HBond Acceptors7
- No.of Rotatable Bonds5
- TPSA108.57
- StatusFDA approved
- AdministrationOral, IV
- PharmacologyA pyridine-sulfonyl urea type loop diuretic mainly used in the management of edema associated with congestive heart failure.
- Absorption_value96.0
- Absorption (description)Rapidly absorbed following oral administration.
- Caco_2N/A
- Bioavailability80.0
- Protein binding99.0
- Volume of distribution (VD)11 to 16.5 L or 0.09 to 0.31 L/kg; this value may increase by approximately double in individuals with hepatic cirrhosis.
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmMetabolized via the hepatic CYP2C8 to 5 metabolites. The major metabolite, M5, is pharmacologically inactive. There are 2 minor metabolites, M1, possessing one-tenth the activity of torasemide, and M3, equal in activity to torasemide. Overall, torasemide appears to account for 80% of the total diuretic activity, while metabolites M1 and M3 account for 9% and 11%, respectively.
- Half life2.2~3.5 h
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySymptoms of overdose include dehydration, hypovolemia, hypotension, hyponatremia, hypokalemia, hypochloremic alkalosis, and hemoconcentration. Oral LD50 in rat is 5 g/kg, and intravenous LD50 in rat is 500 mg/kg.
- LD50 (rat)N/A
- LD50 (mouse)N/A